NASDAQ:ONS - Oncobiologics Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$0.6405 +0.03 (+4.91 %)
(As of 12/10/2018 07:38 AM ET)
Previous Close$0.61
Today's Range$0.61 - $0.6750
52-Week Range$0.57 - $1.53
Volume12,512 shs
Average Volume69,024 shs
Market Capitalization$46.35 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.27
Oncobiologics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha. The company also develops ONS-1045, a bevacizumab biosimilar, which is in a Phase 1 clinical trial that interferes with tumor growth by binding to vascular endothelial growth factor, a protein that stimulates the formation of new blood vessels. Its advanced preclinical product candidate is ONS-1050, a trastuzumab biosimilar, interferes with the human epidermal growth factor receptor 2, a protein that stimulates cell proliferation. Oncobiologics, Inc. has collaboration and license agreements with Selexis SA; IPCA Laboratories Limited; Laboratories Liomont, S.A. de C.V.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was founded in 2010 and is headquartered in Cranbury, New Jersey.

Receive ONS News and Ratings via Email

Sign-up to receive the latest news and ratings for ONS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ONS
Previous SymbolNYSE:ONS
CUSIPN/A
Phone609-619-3990

Debt

Debt-to-Equity RatioN/A
Current Ratio0.41
Quick Ratio0.41

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$3.81 million
Price / Sales12.14
Cash FlowN/A
Price / Cash FlowN/A
Book Value($1.36) per share
Price / Book-0.47

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-38,840,000.00
Net Margins-464.47%
Return on EquityN/A
Return on Assets-93.28%

Miscellaneous

Employees48
Outstanding Shares72,200,000
Market Cap$46.35 million
OptionableNot Optionable

Oncobiologics (NASDAQ:ONS) Frequently Asked Questions

What is Oncobiologics' stock symbol?

Oncobiologics trades on the NASDAQ under the ticker symbol "ONS."

What is the consensus analysts' recommendation for Oncobiologics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncobiologics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Oncobiologics.

Has Oncobiologics been receiving favorable news coverage?

News stories about ONS stock have trended very positive on Monday, InfoTrie reports. The research firm scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oncobiologics earned a daily sentiment score of 3.9 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days.

Who are some of Oncobiologics' key competitors?

Who are Oncobiologics' key executives?

Oncobiologics' management team includes the folowing people:
  • Mr. Lawrence A. Kenyon, Pres, CEO, CFO, Principal Accounting Officer, Company Sec.,Treasurer & Director (Age 52)
  • Dr. Pankaj Mohan, Founder & Director (Age 53)
  • Dr. Kenneth M. Bahrt, Chief Medical Officer (Age 65)
  • Mr. Ralph H. Thurman, Exec. Chairman (Age 69)
  • Rick Gregory, Director of Marketing & Communications

When did Oncobiologics IPO?

(ONS) raised $35 million in an initial public offering (IPO) on Friday, May 13th 2016. The company issued 5,800,000 shares at a price of $6.00 per share. Jefferies and Barclays served as the underwriters for the IPO and Cantor Fitzgerald & Co. was co-manager.

Who are Oncobiologics' major shareholders?

Oncobiologics' stock is owned by many different of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.79%). Company insiders that own Oncobiologics stock include Elizabeth A Yamashita, Kenneth Bahrt, Lawrence A Kenyon, Pankaj Mohan and Stephen J Mcandrew. View Institutional Ownership Trends for Oncobiologics.

Which institutional investors are buying Oncobiologics stock?

ONS stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc.. View Insider Buying and Selling for Oncobiologics.

How do I buy shares of Oncobiologics?

Shares of ONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Oncobiologics' stock price today?

One share of ONS stock can currently be purchased for approximately $0.6405.

How big of a company is Oncobiologics?

Oncobiologics has a market capitalization of $46.35 million and generates $3.81 million in revenue each year. Oncobiologics employs 48 workers across the globe.

What is Oncobiologics' official website?

The official website for Oncobiologics is http://www.oncobiologics.com.

How can I contact Oncobiologics?

Oncobiologics' mailing address is 7 CLARKE DRIVE, CRANBURY NJ, 08512. The company can be reached via phone at 609-619-3990 or via email at [email protected]


MarketBeat Community Rating for Oncobiologics (NASDAQ ONS)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  118 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  237
MarketBeat's community ratings are surveys of what our community members think about Oncobiologics and other stocks. Vote "Outperform" if you believe ONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/10/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel